{"i": ["vildagliptin", "nateglinide plus vildagliptin combination"], "o": []}
{"i": [], "o": []}
{"i": ["vildagliptin", "nateglinide"], "o": []}
{"i": ["nateglinide to vildagliptin )", "nateglinide", "nateglinide plus vildagliptin"], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["glycated hemoglobin"]}
{"i": [], "o": ["mean changes in area under the curve of glucose"]}
{"i": [], "o": ["incidence of hypoglycemic events", "severe hypoglycemia ."]}
{"i": ["vildagliptin to nateglinide"], "o": ["insulin secretion relative to glucose elevation ( ISG )", "mean ISG0"]}
{"i": ["nateglinide to vildagliptin"], "o": ["mean ISG0"]}
{"i": ["vildagliptin", "nateglinide"], "o": ["glycemic control"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["vildagliptin", "nateglinide"], "o": []}
{"i": ["nateglinide to vildagliptin )", "nateglinide", "nateglinide plus vildagliptin"], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["glycated hemoglobin"]}
{"i": [], "o": ["mean changes in area under the curve of glucose"]}
{"i": [], "o": ["incidence of hypoglycemic events", "severe hypoglycemia ."]}
{"i": ["vildagliptin to nateglinide"], "o": ["insulin secretion relative to glucose elevation ( ISG )", "mean ISG0"]}
{"i": ["nateglinide to vildagliptin"], "o": ["mean ISG0"]}
{"i": ["vildagliptin", "nateglinide"], "o": ["glycemic control"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["glinides"], "o": []}
{"i": ["sulfonylurea compounds"], "o": ["overall insulin exposure"]}
{"i": ["glinides"], "o": []}
{"i": [], "o": []}
{"i": ["sulfonylureas"], "o": []}
{"i": ["nateglinide and dipeptidyl peptidase \u2010 IV ( DPP \u2010 IV ) inhibitors"], "o": []}
{"i": ["glinides", "sulfonylurea", "DPP \u2010 IV inhibitors"], "o": []}
{"i": ["nateglinide and vildagliptin", "nateglinide to vildagliptin ."], "o": ["therapeutic efficacy"]}
{"i": [], "o": []}
{"i": ["nateglinide"], "o": []}
{"i": ["sulfonylurea"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["nateglinide \u2010"], "o": []}
{"i": ["nateglinide + vildagliptin", "nateglinide to vildagliptin"], "o": ["safety", "glycemic control ( HbA1c and area under the curve [ AUC ] of serum glucose"]}
{"i": [], "o": ["effects on blood pressure ( BP ) and body mass index ( BMI ).", "secretion of insulin and glucagon , serum lipid profile under standard meal load"]}
{"i": ["oral vildagliptin"], "o": []}
{"i": ["nateglinide"], "o": []}
{"i": ["vildagliptin monotherapy without nateglinide"], "o": []}
{"i": ["diet therapy"], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["plasma adiponectin , BP and BMI"]}
{"i": [], "o": []}
{"i": [], "o": ["serum lipids ( total cholesterol , high \u2010 density lipoprotein cholesterol and triglycerides ) and HbA1c"]}
{"i": [], "o": ["BP"]}
{"i": [], "o": []}
{"i": [], "o": ["general health , compliance with medications , laboratory data , blood pressure , and diet and exercise status"]}
{"i": [], "o": ["laboratory data , BP , BMI and standard meal loading test"]}
{"i": [], "o": ["mean laboratory values"]}
{"i": [], "o": ["hypoglycemic episodes .", "assessment of vital signs , clinical hematology and chemistry , urinalysis", "reporting of adverse events"]}
{"i": ["Vildagliptin", "nateglinide"], "o": []}
{"i": ["ACE , angiotensin \u2010 converting enzyme inhibitor ; ARB , angiotensin"], "o": []}
{"i": [], "o": []}
{"i": ["vildagliptin", "nateglinide", "nateliginide"], "o": []}
{"i": ["carbohydrate"], "o": ["total energy content"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["interleukin ( IL )\u2010 6 , total adiponectin , active GLP \u2010 1 , and high \u2010 sensitivity C reactive protein ( hsCRP )", "glucose , insulin , glucagon and lipids ( triglycerides [ TG ], low \u2010 density lipoprotein cholesterol , high \u2010 density lipoprotein cholesterol and total cholesterol )"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["AUC"]}
{"i": [], "o": []}
{"i": [], "o": ["rates"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["switching to vildagliptin", "combination therapy"], "o": []}
{"i": [], "o": []}
{"i": ["vildagliptin"], "o": ["mild hypoglycemia", "liver dysfunction"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["vildagliptin", "vildagliptin with nateglinide"], "o": ["mean HbA1c"]}
{"i": [], "o": ["HbA1c"]}
{"i": [], "o": ["mean HbA1c level", "HbA1c"]}
{"i": [], "o": ["mean HbA1c level"]}
{"i": [], "o": ["mean change in HbA1c"]}
{"i": [], "o": ["target HbA1c"]}
{"i": [], "o": ["mean serum glucose concentrations", "fasting serum glucose level"]}
{"i": ["nateglinide to vildagliptin", "vildagliptin to nateglinide"], "o": ["glucose levels"]}
{"i": [], "o": ["fasting glucose level"]}
{"i": ["vildagliptin to nateglinide", "nateglinide to vildagliptin"], "o": ["mean AUC of glucose", "mean AUC0 \u2013 180 min glucose"]}
{"i": ["vildagliptin", "nateglinide"], "o": ["mean change in AUC0 \u2013 180 min glucose"]}
{"i": ["vildagliptin", "nateglinide ."], "o": ["fasting and postprandial hyperglycemia"]}
{"i": [], "o": ["serum insulin", "mean change in insulin secretion relative to glucose elevation ( ISG )"]}
{"i": ["vildagliptin to nateglinide"], "o": ["serum insulin levels"]}
{"i": ["nateglinide to vildagliptin"], "o": ["serum insulin levels"]}
{"i": ["nateglinide", "vildagliptin to nateglinide"], "o": ["mean change in ISG0 \u2013 180 min"]}
{"i": [], "o": ["ISG0", "glycemic control"]}
{"i": ["vildagliptin", "nateglinide"], "o": ["insulin secretion", "early phase insulin secretion"]}
{"i": [], "o": []}
{"i": ["nateglinide"], "o": []}
{"i": [], "o": ["glucagon", "AUC0 \u2013 180 min glucagon"]}
{"i": [], "o": ["AUC of glucagon"]}
{"i": [], "o": ["AUCs of glucagon"]}
{"i": [], "o": ["plasma active GLP \u2010 1 concentrations"]}
{"i": [], "o": []}
{"i": [], "o": ["postprandial adiponectin , IL \u2010 6 and hsCRP"]}
{"i": [], "o": ["lipid metabolism", "fasting serum low \u2010 density lipoprotein cholesterol"]}
{"i": [], "o": ["overall incidence of adverse events"]}
{"i": [], "o": ["adverse events", "hypoglycemia ."]}
{"i": [], "o": ["Mild nausea and liver dysfunction"]}
{"i": [], "o": ["serious adverse events"]}
{"i": [], "o": ["Hypoglycemic events", "severe hypoglycemia ."]}
{"i": ["vildagliptin"], "o": ["hypoglycemic events"]}
{"i": ["nateglinide ."], "o": ["hypoglycemia \u2010 related symptoms"]}
{"i": [], "o": ["bodyweight"]}
{"i": [], "o": ["liver transaminases .", "hematological , biochemical and urinary parameters"]}
{"i": ["vildagliptin", "nateglinide", "nateginide"], "o": []}
{"i": ["Glinides"], "o": []}
{"i": ["sulfonylureas"], "o": ["insulin secretion"]}
{"i": ["vildagliptin and nateglinde"], "o": ["glycemic control ."]}
{"i": ["Vildagliptin", "vildagliptin", "nateglinide"], "o": ["HbA1c"]}
{"i": [], "o": ["HbA1c"]}
{"i": [], "o": ["HbA1c"]}
{"i": ["vildagliptin", "nateglinide"], "o": ["glycemic control"]}
{"i": ["Nateglinide"], "o": []}
{"i": ["nateglinide and vildagliptin", "nateglinide to vildagliptin"], "o": ["insulin secretion relative to glucose elevation"]}
{"i": [], "o": ["insulin secretion", "ISG0 \u2013 30 min"]}
{"i": ["vildagliptin", "nateglinide"], "o": ["insulin secretion"]}
{"i": ["DPP \u2010 IV inhibitor"], "o": []}
{"i": ["placebo , glibenclamide , vildagliptin or both"], "o": ["insulin secretion"]}
{"i": ["Glibenclamide"], "o": ["insulin and C \u2010 peptide responses", "hypoglycemia ."]}
{"i": ["Vildagliptin", "placebo"], "o": ["insulin secretory responses"]}
{"i": ["glibenclamide", "Vildagliptin plus glibenclamide"], "o": ["insulin and C \u2010 peptide responses"]}
{"i": ["alogliptin"], "o": ["insulin secretion"]}
{"i": ["alogliptin"], "o": ["insulin secretion .", "glucose excursion"]}
{"i": ["glinide and incretin \u2010 related drugs"], "o": []}
{"i": ["nateglinide", "GLP \u2010 1"], "o": []}
{"i": ["nateglinide"], "o": ["Plasma glucose responses", "mean AUC0 \u2013 180 min insulin responses"]}
{"i": ["nateglinide", "GLP \u2010 1"], "o": ["active GLP \u2010 1 concentration", "plasma DPP \u2010 IV activity"]}
{"i": ["nateglinide and vildagliptin"], "o": []}
{"i": [], "o": ["active GLP \u2010 1 concentration"]}
{"i": ["nateglinide"], "o": []}
{"i": ["nateglinide and vildagliptin"], "o": []}
{"i": ["nateglinide"], "o": ["postprandial glucose level", "early \u2010 phase insulin secretion"]}
{"i": ["nateglinide", "nateglinide with vildagliptin"], "o": ["postprandial hyperglycemia", "AUC0 \u2013 60 min insulin"]}
{"i": [], "o": ["ISG0"]}
{"i": ["vildagliptin"], "o": ["tolerated", "overall incidence of adverse effects"]}
{"i": [], "o": ["discontinuation", "adverse effects"]}
{"i": [], "o": ["overall incidence of hypoglycemia"]}
{"i": ["vildagliptin", "nateglinide"], "o": ["severe hypoglycemia .", "glycemic control", "severe hypoglycemia"]}
{"i": ["vildagliptin"], "o": ["liver dysfunction", "liver enzymes"]}
{"i": [], "o": ["Bodyweight"]}
{"i": ["vildagliptin", "vildagliptin and sulfonylurea", "sulfonylurea26"], "o": ["bodyweight"]}
{"i": ["placebo", "vildagliptin plus glimepiride"], "o": ["bodyweight"]}
{"i": ["vildagliptin", "thiazolidinediones28", "nateglinide"], "o": ["bodyweight"]}
{"i": ["vildagliptin and nateglinide"], "o": ["target HbA1c"]}
{"i": [], "o": ["incidence of hypoglycemia", "severe hypoglycemia ."]}
{"i": ["vildagliptin", "nateglinide"], "o": []}
{"i": ["nateglinide"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["vildagliptin", "nateglinide"], "o": ["glycemic control and insulin secretion"]}
